Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 14/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.44 |
| ▸ | HRH1 | P35367 | 5/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.44 |
| ▸ | HTR2B | P41595 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4256756 | 1.00 | CNR1 (0.54) | CNR1KCNH2AURKBMCHR1HPGD | |
| SCHEMBL4266604 | 0.91 | RAB9A (0.59) | CNR1KCNH2AURKBMCHR1HPGD | |
| SCHEMBL4266600 | 0.91 | RAB9A (0.59) | CNR1KCNH2AURKBMCHR1HPGD | |
| SCHEMBL4265569 | 0.85 | MCHR1 (0.46) | CNR1KCNH2AURKBMCHR1HPGD | |
| SCHEMBL4265549 | 0.85 | MCHR1 (0.46) | CNR1KCNH2AURKBMCHR1HPGD | |
| SCHEMBL4258736 | 0.84 | CNR1 (0.48) | CNR1KCNH2AURKBMCHR1ADRA2A | |
| SCHEMBL4258733 | 0.84 | CNR1 (0.48) | CNR1KCNH2AURKBMCHR1ADRA2A | |
| SCHEMBL4266403 | 0.84 | CNR1 (0.56) | CNR1KCNH2AURKBMCHR1HPGD | |
| SCHEMBL4266415 | 0.84 | CNR1 (0.56) | CNR1KCNH2AURKBMCHR1HPGD | |
| SCHEMBL6463044 | 0.82 | CNR1 (0.80) | CNR1KCNH2AURKBMCHR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | claimed |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | GPR119, HCRTR2, MCHR1 | CNR1 114/4885KCNH2 3317/4885AURKB 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.